Bausch + Lomb Corporation
Bausch + Lomb Corporation
Your view on BLCO
Overview
What the company does, where it operates, and who runs it.
About Bausch + Lomb Corporation
- Industry
- Medical - Instruments & Supplies
- Sector
- Healthcare
- CEO
- Brenton L. Saunders
- Headquarters
- 520 Applewood Crescent, Vaughan, ON, CA
- Industry
- Medical - Instruments & Supplies
- Sector
- Healthcare
- CEO
- Brenton L. Saunders
- Headquarters
- 520 Applewood Crescent, Vaughan, ON, CA
Bausch + Lomb Corporation operates as an eye health company worldwide. It operates through three segments: Vision Care/Consumer Health Care, Ophthalmic Pharmaceuticals, and Surgical.
The Vision Care/Consumer Health Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products, over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions comprising eye allergies, conjunctivitis, and dry eye.
The Ophthalmic Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of eye conditions, such as glaucoma, ocular hypertension, and retinal diseases; and contact lenses for therapeutic use.
The Surgical segment provides tools and technologies for the treatment of cataracts, and vitreous and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices. The company was founded in 1853 and is headquartered in Vaughan, Canada.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Bausch + Lomb Corporation, and the rating behind it. BLCO last traded at $17.25; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Bausch + Lomb Corporation. Starting points for Bausch + Lomb Corporation: EPS -$0.48, beta 0.56 — an Medical - Instruments & Supplies name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Bausch + Lomb Corporation. Bausch + Lomb Corporation does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Bausch + Lomb Corporation. Trailing twelve-month EPS for Bausch + Lomb Corporation stands at -$0.48. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Bausch + Lomb Corporation. Bausch + Lomb Corporation has reported as a listed company since 2022. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Bausch + Lomb Corporation valued side by side against its closest peers. Bausch + Lomb Corporation is measured against Medical - Instruments & Supplies peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Bausch + Lomb Corporation, and how their positions are changing. At a $6.16B market value, institutional positions materially move Bausch + Lomb Corporation's register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Bausch + Lomb Corporation executives and directors. Shares of Bausch + Lomb Corporation have traded between $10.45 and $20.71 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Bausch + Lomb Corporation. Bausch + Lomb Corporation is a $6.16B Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Bausch + Lomb Corporation. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Bausch + Lomb Corporation. Coverage tracks Bausch + Lomb Corporation within Medical - Instruments & Supplies (Healthcare). Press releases and market coverage, newest first.